Kraig Biocraft Laboratories to Host Corporate Conference Call
February 19 2013 - 6:05AM
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Kraig" or "The
Company") announces an advance conference call advisory for all
shareholders and other interested parties.
The Company plans to host a conference call for the purpose of
discussing production, commercialization and scientific milestones
as well as other corporate developments, featuring the Kraig's
founder and CEO, Kim Thompson and is tentatively scheduled for
late-March to mid-April, pending the travel schedule of Thompson
and members of the scientific team.
Kraig recently announced that it signed a memorandum of
understanding with SSM Industries Inc. (www.Ssmind.com) to jointly
commercialize Kraig's Monster Silk(TM) recombinant spider silk.
Other recent announcements included that the Company launched and
is accelerating its Monster Silk(TM) pilot production program, as
well as that it succeeded in creating "Big Red", a new type of
recombinant spider silk.
The Company plans on releasing definitive details, including
call-in details, time and format, at least one week prior to
conference call and shareholders are invited to submit questions to
ir@kraiglabs.com.
About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully
reporting biotechnology company that has achieved a series of
scientific breakthroughs in the area of spider silk technology with
implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "estimated," "hopes," "develops," "researching,"
"research," "potential," "could" or other words or phrases of
similar import. Similarly, statements in this release that describe
the Company's business strategy, outlook, objectives, plans,
intentions or goals should all be considered forward-looking
statements. All such forward-looking statements are subject to
certain risks and uncertainties that could cause actual results to
differ materially from those in forward-looking statements.
Management cautions that its ability to further its research, and
create commercially-viable products may be affected by the
competitive environment, the Company's financial condition and its
ability to raise sufficient capital to meet the financial
obligations of its business plan and to fund its continuing
operations.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any security and shall not
constitute an offer, solicitation or sale of any securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of such jurisdiction.
CONTACT: Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@kraiglabs.com
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2024 to Jun 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Jun 2023 to Jun 2024